Contribution of Nuclear Cardiology to the Diagnosis of the Various Stages of Coronary Artery Disease

1982 ◽  
pp. 146-154
Author(s):  
W. E. Adam ◽  
F. Bitter ◽  
M. Stauch
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Nuclear Cardiology ◽  
Artery Disease

Cost Effectiveness of Imaging with Nuclear Cardiology

2015 ◽  
Author(s):  
Lawrence M. Phillips ◽  
Leslee J. Shaw
Keyword(s):  
Coronary Artery Disease ◽  
Chest Pain ◽  
Coronary Artery ◽  
Nuclear Cardiology ◽  
The Elderly ◽  
Evidence Base ◽  
Negative Evidence ◽  
High Likelihood ◽  
Imaging Data ◽  
Artery Disease

This chapter focuses on the economic data available for cardiovascular (CV) imaging. The total costs of testing are substantively lower than those associated with invasive procedures. There are several ongoing randomized trials, such as the PROMISE trial, that may further add to our evidence base on the cost implications of CV imaging. Data for stress nuclear cardiology supports its utility in terms of a high prognostic accuracy and that this test is economically attractive; notably for patients with a high likelihood of coronary artery disease. Data also supports that this benefit does not only include patients with known coronary artery disease but also the high likelihood subsets of the elderly or functionally impaired where ischemic findings play a fundamental role in ischemia-guided management. Importantly, more recent data support that alternative testing strategies have reduced cost in subsets of patients including lower risk women with stable chest pain and in the acute evaluation of low risk chest pain in the ED. Negative evidence is extremely important for the field of CV imaging and this more recent data should be embraced as defining our limitations in nuclear cardiology.

Sign in / Sign up

Export Citation Format

Share Document